UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/588,695	08/08/2006	Friedbert Wechs	2037.7	8355	
	7590 08/17/201 ASSOCIATES, P.C.	1	EXAMINER		
3125 SPRINGBANK LANE			GONZALEZ, MADELINE		
SUITE G CHARLOTTE, NC 28226			ART UNIT	PAPER NUMBER	
			1778		
			MAIL DATE	DELIVERY MODE	
			08/17/2011	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)	
	10/588,695	WECHS ET AL.	
Office Action Summary	Examiner	Art Unit	
	MADELINE GONZALEZ	1778	
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence ad	dress
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be time will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	I. lely filed the mailing date of this co (35 U.S.C. § 133).	
Status			
1) ☐ Responsive to communication(s) filed on 18 M. 2a) ☐ This action is FINAL . 2b) ☐ This 3) ☐ Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final. ace except for formal matters, pro		e merits is
Disposition of Claims			
4) ☐ Claim(s) 1.4.5 and 7-20 is/are pending in the a 4a) Of the above claim(s) 10-17 is/are withdraw 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1.4.5.7-9 and 18-20 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or	rn from consideration.		
Application Papers			
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the of Replacement drawing sheet(s) including the correction 11) The oath or declaration is objected to by the Ex	epted or b) \square objected to by the Edrawing(s) be held in abeyance. See on is required if the drawing(s) is obj	937 CFR 1.85(a). ected to. See 37 CF	` '
Priority under 35 U.S.C. § 119			
 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list of 	s have been received. s have been received in Application ity documents have been receive (PCT Rule 17.2(a)).	on No ed in this National	Stage
Attachment(s) 1) Notice of References Cited (PTO-892)	4) Interview Summary		
Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:		

DETAILED ACTION

Claim Status

Claims 1, 4, 5, 7-9 and 18-20 are rejected.

Claims 2, 3 and 6 have been cancelled.

Claims 10-17 are withdrawn.

Claim Objections

Claim 1 is objected to because of the following informalities:

The limitation "the lumen" in line 17 lacks antecedent basis.

Appropriate correction is required.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1, 4, 5, 7-9 and 18-20 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 1 recites the limitation "wherein after prior drying" in line 21. This limitation is confusing because it is not clear what applicant means by "after prior".

Application/Control Number: 10/588,695 Page 3

Art Unit: 1778

Claim Rejections - 35 USC §103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

<u>Claims 1, 4, 5, 7-9, 19 and 20 are rejected under 35 U.S.C. 103(a) as obvious over Wang et al. (U.S. 6,565,782) [hereinafter Wang].</u>

With respect to claims 1, 8, 9 and 19, Wang discloses membrane having:

- a hydrophilic, watter-wettable membrane being based on;
 - a hydrophobic first polymer, such as polysulfone polymer (aromatic sulfone polymer) (see col. 5, lines 52-54); and
 - a hydrophilic second polymer such as polyvinylpyrrolidone (see col. 5, lines 54-55);
 - possessing an open-pored, integrally asymmetric structure across its wall, with a porous separating layer on its inner surface facing the lumen and an open-pored supporting layer (see col. 5, lines 31-38);
 and
 - whereby the membrane in the dry state is free from pore-stabilizing additives in the membrane wall (see col. 10, line 27 through col. 13, line 48).

Wang lacks the specific thickness of the separating layer, the specific ultrafiltration rate in albumin solution, the minimum sieving coefficient for cytochrome c

and the maximum sieving coefficient for albumin. However, Wang teaches a membrane made of the same material as claimed by applicant and a similar process of making the membrane (see col. 10, line 27 through col. 13, line 48). It is therefore inherent that the membrane has the same ultrafiltration rate and sieving coefficients claimed by applicant, absent evidence to the contrary. Furthermore, it would have been obvious to obtain the specific ultrafiltration rate and sieving coefficients for the membrane disclosed by Wang since the court have held that "where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation (see In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955)).

With respect to claim 4, Wang discloses wherein the aromatic sulfone polymer is polysulfone (see col. 5, lines 52-54).

With respect to claim 5, Wang discloses wherein the hydrophobic first polymer is a polysulfone or a polyethersulfone (see col. 5, lines 52-54).

With respect to claim 7, Wang discloses wherein the supporting layer extends from the separating layer across essentially the entire wall of the hollow-fiber membrane, has a sponge-like structure and is free from finger pores, as shown in Figs. 1C and 2A.

Art Unit: 1778

With respect to claim 20, Wang discloses wherein the supporting layer being essentially free from polyelectrolyte with negative free charges (see col. 10, line 27 through col. 13, line 48).

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 18 is rejected under 35 U.S.C. 103(a) as being unpatentable over a combination of Wang (U.S. 6,565,782) and Chu et al. (U.S. 4,604,208) [hereinafter Chu]

With respect to claim 18, Wang teaches that the membrane can be further modified by charge modification of the membrane surface in order to remove or exchange ions as a step in a filtration process (see col. 7, lines 27-37). Wang lacks a polyelectrolyte with negative fixed charges physically bound in the separating layer.

Chu teaches an anionic charge modified microporous membrane wherein a polyelectrolyte with negative charges is physically bound in the separating layer (see col. 9, lines 59-66) in order to enhance the filtration membrane performance of the membrane for charged particulate contaminants without decreasing the pore size if the membrane (see col. 5, lines 28-35). It would have been obvious to provide the membrane disclosed by Wang with a polyelectrolyte with negative fixed charges

Art Unit: 1778

physically bound in the separating layer, as taught by Chu, in order to enhance the filtration membrane performance of the membrane for charged particulate contaminants without decreasing the pore size of the membrane (see col. 5, lines 28-35) and since Wang is already suggesting that the membrane can be further modified by charge modification of the membrane surface in order to remove or exchange ions as a step in a filtration process (see col. 7, lines 27-37).

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1, 4, 5, 7-9, and 18-20 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 12, 14-16 and 18 of copending Application No. 10/588,016. Although the conflicting claims are not identical, they are not patentably distinct from each other because both disclose a hollow fiber membrane with polyelectrolyte bound in the separating layer.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Response to Arguments

Applicant's arguments filed on March 18, 2010 have been fully considered but they are not persuasive.

In response to applicant's argument that Wang discloses membranes having pore size greater than 0.1 micron: It is noted that a pore size is not recited in the

Art Unit: 1778

rejected claim(s) and therefore, this argument is not relevant to the claims. Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993).

In response to applicant's argument that Wang fails to come even close to disclosing the general conditions of Applicant's claim 1 and, therefore, it would have not being obvious to discover the optimum or workable ranges through routine experimentation: Wang teaches a membrane made of the same material as claimed by applicant, i.e., a hydrophobic first polymer, such as polysulfone polymer (aromatic sulfone polymer) (see col. 5, lines 52-54); and a hydrophilic second polymer such as polyvinylpyrrolidone (see col. 5, lines 54-55); possessing an open-pored, integrally asymmetric structure across its wall, with a porous separating layer on its inner surface facing the lumen and an open-pored supporting layer (see col. 5, lines 31-38); and whereby the membrane in the dry state is free from pore-stabilizing additives in the membrane wall (see col. 10, line 27 through col. 13, line 48). These are the general conditions of the membrane and are met by Wang, and therefore, it would have being obvious to discover the optimum or workable ranges through routine experimentation, as stated above.

In response to applicant's argument that Wang does not disclose membranes for hemodyalisis, hemodiafiltration or hemofiltration, a recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior

Application/Control Number: 10/588,695 Page 9

Art Unit: 1778

art. If the prior art structure is capable of performing the intended use, then it meets the claim. In this case, the membrane disclosed by Wang is capable of performing the intended use since Wang teaches that the membrane can be used in blood separation protocols (see col. 13, lines 38-45).

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MADELINE GONZALEZ whose telephone number is (571)272-5502. The examiner can normally be reached on M, W, Th, F- 8:30am-5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Nam Nguyen can be reached on 571-272-1342. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/588,695 Page 10

Art Unit: 1778

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Nam X Nguyen/ Supervisory Patent Examiner, Art Unit 1778

Madeline Gonzalez Patent Examiner August 11, 2011